Novo Nordisk (NVO) has again increased its offer for weight-loss drug start-up Metsera (MTSR) in an effort to beat out a sweetened offer from Pfizer (PFE), Drew Armstrong of Endpoints News reports, citing people familiar with the matter. The Financial Times reported on Wednesday that Pfizer had matched Novo Nordisk’s offer to acquire Metsera for up to $10B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly price target raised to $1,100 from $930 at BMO Capital
- Novo Nordisk Reports Strong Sales Growth in 2025
- Pfizer matches Novo Nordisk’s offer for Metsera, FT reports
- Pfizer plans to sweeten offer for Metsera, WSJ reports
- Pfizer says ‘we remain confident in the merits of our claims’ against Metsera